ARTIVA BIOTHERAPEUTICS INC Financials
ARTIVA BIOTHERAPEUTICS INC (ARTV) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Artiva’s development-stage model pairs escalating research investment with heavier cash consumption despite a lightly leveraged balance sheet.
R&D spending reached$69.5M in FY2025, up from$50.3M in FY2024. Over the same periods, operating cash flow moved from-$55.0M to-$76.8M , so the larger research program coincided with greater cash consumption rather than internally funded operations.
FY2025 net loss was
The balance sheet remains lightly burdened by liabilities:
Financial Health Signals
ARTIVA BIOTHERAPEUTICS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
ARTIVA BIOTHERAPEUTICS INC scores 11.58, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($575.4M) relative to total liabilities ($21.0M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
ARTIVA BIOTHERAPEUTICS INC passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
ARTIVA BIOTHERAPEUTICS INC reported a net loss of $83.9M while operations used $76.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
ARTIVA BIOTHERAPEUTICS INC generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
ARTIVA BIOTHERAPEUTICS INC's EBITDA was -$87.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 34.5% from the prior year.
ARTIVA BIOTHERAPEUTICS INC reported -$83.9M in net income in fiscal year 2025. This represents a decrease of 28.3% from the prior year.
ARTIVA BIOTHERAPEUTICS INC earned -$3.43 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
ARTIVA BIOTHERAPEUTICS INC recorded an outflow of $79.3M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 42.5% from the prior year.
ARTIVA BIOTHERAPEUTICS INC held $26.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
ARTIVA BIOTHERAPEUTICS INC's ROE was -76.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 41.2 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
ARTIVA BIOTHERAPEUTICS INC invested $69.5M in research and development in fiscal year 2025. This represents an increase of 38.2% from the prior year.
ARTIVA BIOTHERAPEUTICS INC invested $2.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 303.0% from the prior year.
Not reported for fiscal year 2025.
ARTV Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | N/A | $0-100.0% | $251K-99.3% | $33.5M |
| R&D Expenses | N/A | $69.5M+38.2% | $50.3M+0.2% | $50.3M |
| SG&A Expenses | N/A | $20.3M+17.8% | $17.2M+23.7% | $13.9M |
| Operating Income | N/A | -$89.8M-33.5% | -$67.3M-119.4% | -$30.7M |
| Income Tax | N/A | $0 | $0-100.0% | $72K |
| Net Income | N/A | -$83.9M-28.3% | -$65.4M-127.6% | -$28.7M |
| EPS (Diluted) | — | -$3.43 | -$5.81 | -$35.78 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ARTV Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Total Assets | $130.9M-37.5% | $209.6M+99.4% | $105.1M |
| Current Assets | $112.7M-40.3% | $188.6M+136.3% | $79.8M |
| Cash & Equivalents | $26.7M-33.6% | $40.2M-24.8% | $53.5M |
| Accounts Receivable | N/A | $0-100.0% | $1.0M |
| Total Liabilities | $21.0M-8.6% | $22.9M-91.4% | $267.1M |
| Current Liabilities | $13.1M+6.8% | $12.3M+0.2% | $12.2M |
| Total Equity | $110.0M-41.1% | $186.6M+215.2% | -$162.0M |
| Retained Earnings | -$330.5M-34.0% | -$246.7M-36.1% | -$181.3M |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
ARTV Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Operating Cash Flow | -$75.2M | -$76.8M-39.5% | -$55.0M-16.0% | -$47.4M |
| Capital Expenditures | $1.7M | $2.6M+303.0% | $642K-80.3% | $3.3M |
| Free Cash Flow | -$76.9M | -$79.3M-42.5% | -$55.7M-9.8% | -$50.7M |
| Investing Cash Flow | $65.2M | $63.4M+152.6% | -$120.5M-363.8% | -$26.0M |
| Financing Cash Flow | $283.0M | $9K-100.0% | $162.2M+565.1% | $24.4M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ARTV Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Operating Margin | N/A | -26805.6% | -91.6% |
| Net Margin | N/A | -26045.0% | -85.8% |
| Return on Equity | -76.3%-41.2pp | -35.0% | N/A |
| Return on Assets | -64.0%-32.9pp | -31.2%-3.9pp | -27.3% |
| Current Ratio | 8.61-6.8x | 15.39+8.9x | 6.53 |
| Debt-to-Equity | 0.19+0.1x | 0.12 | N/A |
| FCF Margin | N/A | -22180.9% | -151.3% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where ARTIVA BIOTHERAPEUTICS INC Ranks
Frequently Asked Questions
What is ARTIVA BIOTHERAPEUTICS INC's annual revenue?
ARTIVA BIOTHERAPEUTICS INC (ARTV) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is ARTIVA BIOTHERAPEUTICS INC's revenue growing?
ARTIVA BIOTHERAPEUTICS INC (ARTV) revenue declined by 100.0% year-over-year, from $251K to $0 in fiscal year 2025.
Is ARTIVA BIOTHERAPEUTICS INC profitable?
No, ARTIVA BIOTHERAPEUTICS INC (ARTV) reported a net income of -$83.9M in fiscal year 2025.
What is ARTIVA BIOTHERAPEUTICS INC's EBITDA?
ARTIVA BIOTHERAPEUTICS INC (ARTV) had EBITDA of -$87.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is ARTIVA BIOTHERAPEUTICS INC's return on equity (ROE)?
ARTIVA BIOTHERAPEUTICS INC (ARTV) has a return on equity of -76.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is ARTIVA BIOTHERAPEUTICS INC's free cash flow?
ARTIVA BIOTHERAPEUTICS INC (ARTV) recorded an outflow of $79.3M in free cash flow during fiscal year 2025. This represents a -42.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is ARTIVA BIOTHERAPEUTICS INC's operating cash flow?
ARTIVA BIOTHERAPEUTICS INC (ARTV) recorded an outflow of $76.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are ARTIVA BIOTHERAPEUTICS INC's total assets?
ARTIVA BIOTHERAPEUTICS INC (ARTV) had $130.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are ARTIVA BIOTHERAPEUTICS INC's capital expenditures?
ARTIVA BIOTHERAPEUTICS INC (ARTV) invested $2.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does ARTIVA BIOTHERAPEUTICS INC spend on research and development?
ARTIVA BIOTHERAPEUTICS INC (ARTV) invested $69.5M in research and development during fiscal year 2025.
What is ARTIVA BIOTHERAPEUTICS INC's current ratio?
ARTIVA BIOTHERAPEUTICS INC (ARTV) had a current ratio of 8.61 as of fiscal year 2025, which is generally considered healthy.
What is ARTIVA BIOTHERAPEUTICS INC's debt-to-equity ratio?
ARTIVA BIOTHERAPEUTICS INC (ARTV) had a debt-to-equity ratio of 0.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is ARTIVA BIOTHERAPEUTICS INC's return on assets (ROA)?
ARTIVA BIOTHERAPEUTICS INC (ARTV) had a return on assets of -64.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does ARTIVA BIOTHERAPEUTICS INC's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, ARTIVA BIOTHERAPEUTICS INC (ARTV) held $108.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $76.8M over that year. Dividing the one by the other, the reported balance equals about 17 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is ARTIVA BIOTHERAPEUTICS INC's Altman Z-Score?
ARTIVA BIOTHERAPEUTICS INC (ARTV) has an Altman Z-Score of 11.58, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is ARTIVA BIOTHERAPEUTICS INC's Piotroski F-Score?
ARTIVA BIOTHERAPEUTICS INC (ARTV) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ARTIVA BIOTHERAPEUTICS INC's earnings high quality?
ARTIVA BIOTHERAPEUTICS INC (ARTV) reported a net loss of $83.9M while operations used $76.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.